NCT01013987 - Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Conditions

HIV-1 Adults PatientsAIDSTriple Class Failure

Interventions

DRUG

maraviroc

maraviroc: one 150 mg pill twice daily

DRUG

Raltegravir

raltegravir : one 400 mg pill twice daily

DRUG

Darunavir/ritonavir

"* darunavir : two 300 mg pills twice daily with meal~* ritonavir: one 100 mg pill twice daily with meal"

Trial Locations (1)

RECRUITING

Fundación Huésped, Ciudad de Buenos Aires